TrialBritish journal of cancer2014

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.

Y-K Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.